Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis

NCT01188733 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Cirrhosis
Portal Hypertension
Esophageal Varices

Interventions

DRUG: Long acting octreotide 10mg
DRUG: Long acting Octreotide 30mg
DRUG: Saline

Sponsor

Mayo Clinic